Search

Displaying results 6781 - 6790 of 10000 in total
  1. Drug

    Navicixizumab

    go.drugbank.com/drugs/DB12634
    Investigational

    Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).

  2. Drug

    Volenrelaxin

    go.drugbank.com/drugs/DB21750
    Investigational

    Volenrelaxin is under investigation in clinical trial NCT06598631 (Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease).

  3. Drug

    Edaxeterkib

    go.drugbank.com/drugs/DB21490
    Investigational

    Edaxeterkib is under investigation in clinical trial NCT03051035 (First-in-Human Study of KO-947 in Non-Hematological Malignancies). Edaxeterkib has a monoisotopic molecular weight of 469.22 Da. … The usage of the INN stem '-terkib' in the name indicates that Edaxeterkib is a extracellular signal-regulated kinase (ERK) inhibitor.

  4. Drug

    Egaptivon pegol

    go.drugbank.com/drugs/DB05202
    Investigational

    Egaptivon pegol, formerly known as ARC1779, is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets.

  5. Drug

    Vitespen

    go.drugbank.com/drugs/DB06400
    Investigational

  6. Drug

    Cobolimab

    go.drugbank.com/drugs/DB16372
    Investigational

    Cobolimab is under investigation in clinical trial NCT04655976 (Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants).

  7. Drug

    Rulonilimab

    go.drugbank.com/drugs/DB18922
    Investigational

    Rulonilimab is under investigation in clinical trial NCT05408221 (The Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma).

  8. Drug

    Fallypride

    go.drugbank.com/drugs/DB15167
    Investigational

    Fallypride is under investigation in clinical trial NCT02310360 (Striatal and Extra-striatal Dopamine Release in Response to Food in Healthy Humans).

  9. Drug

    KP-1461

    go.drugbank.com/drugs/DB05644
    Investigational

    KP-1461 is a potent, non-chain-terminating, mutagenic deoxyribonucleoside analogue. Designated a DNA covert nucleoside, the drug consists of a modified base that incorporates randomly into HIV and pairs with multiple bases.

  10. Drug

    GALE-301

    go.drugbank.com/drugs/DB17262
    Investigational

    GALE-301 is an investigational cancer immunotherapy. … It is made up of E39, an immunogenic peptide derived from the folate binding protein (FBP), and an immune adjuvant, granulocyte macrophage-colony stimulating factor (GM-CSF).[A254696,L44166,L44171]